Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SINDAS: SBRT + TKI in EGFRm NSCLC
NCT02893332Phase 3Terminated
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2016
- Primary completion
- Aug 2020
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Progression-Free Survival at 4 years. Started Jan 2016; status: terminated.
Beyond the preview
Go deeper on NCT02893332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893332.